162 related articles for article (PubMed ID: 38579174)
1. Pan-cancer analysis of Sushi domain-containing protein 4 (SUSD4) and validated in colorectal cancer.
Zhong Y; Zheng C; Zhang W; Wu H; Zhang Q; Li D; Ju H; Feng H; Chen Y; Fan Y; Chen W; Wang M; Wang G
Aging (Albany NY); 2024 Apr; 16(7):6417-6444. PubMed ID: 38579174
[TBL] [Abstract][Full Text] [Related]
2. The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients.
Englund E; Reitsma B; King BC; Escudero-Esparza A; Owen S; Orimo A; Okroj M; Anagnostaki L; Jiang WG; Jirström K; Blom AM
BMC Cancer; 2015 Oct; 15():737. PubMed ID: 26480818
[TBL] [Abstract][Full Text] [Related]
3. Sushi domain-containing protein 4 binds to epithelial growth factor receptor and initiates autophagy in an EGFR phosphorylation independent manner.
Papadakos KS; Ekström A; Slipek P; Skourti E; Reid S; Pietras K; Blom AM
J Exp Clin Cancer Res; 2022 Dec; 41(1):363. PubMed ID: 36578014
[TBL] [Abstract][Full Text] [Related]
4. Sushi domain-containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase.
Holmquist E; Okroj M; Nodin B; Jirström K; Blom AM
FASEB J; 2013 Jun; 27(6):2355-66. PubMed ID: 23482636
[TBL] [Abstract][Full Text] [Related]
5. The Complement Regulator Susd4 Influences Nervous-System Function and Neuronal Morphology in Mice.
Zhu H; Meissner LE; Byrnes C; Tuymetova G; Tifft CJ; Proia RL
iScience; 2020 Mar; 23(3):100957. PubMed ID: 32179479
[TBL] [Abstract][Full Text] [Related]
6. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
[TBL] [Abstract][Full Text] [Related]
7. Tissue distribution and functional analysis of Sushi domain-containing protein 4.
Tu Z; Cohen M; Bu H; Lin F
Am J Pathol; 2010 May; 176(5):2378-84. PubMed ID: 20348246
[TBL] [Abstract][Full Text] [Related]
8. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
9. KIF3C: an emerging biomarker with prognostic and immune implications across pan-cancer types and its experiment validation in gastric cancer.
Zhong Q; Hong W; Xiong L
Aging (Albany NY); 2024 Mar; 16(7):6163-6187. PubMed ID: 38552217
[TBL] [Abstract][Full Text] [Related]
10. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Pennel KAF; Hatthakarnkul P; Wood CS; Lian GY; Al-Badran SSF; Quinn JA; Legrini A; Inthagard J; Alexander PG; van Wyk H; Kurniawan A; Hashmi U; Gillespie MA; Mills M; Ammar A; Hay J; Andersen D; Nixon C; Rebus S; Chang DK; Kelly C; Harkin A; Graham J; Church D; Tomlinson I; Saunders M; Iveson T; Lannagan TRM; Jackstadt R; Maka N; Horgan PG; Roxburgh CSD; Sansom OJ; McMillan DC; Steele CW; Jamieson NB; Park JH; Roseweir AK; Edwards J
J Exp Clin Cancer Res; 2024 Mar; 43(1):64. PubMed ID: 38424636
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
Yu C; Hong H; Lu J; Zhao X; Hu W; Zhang S; Zong Y; Mao Z; Li J; Wang M; Feng B; Sun J; Zheng M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806905. PubMed ID: 30336768
[TBL] [Abstract][Full Text] [Related]
12. EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway.
Shen A; Chen Y; Liu L; Huang Y; Chen H; Qi F; Lin J; Shen Z; Wu X; Wu M; Li Q; Qiu L; Yu N; Sferra TJ; Peng J
Cancer Res; 2019 May; 79(9):2257-2270. PubMed ID: 30862720
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancer.
Li JW; Huang CZ; Li JH; Yuan JH; Chen QH; Zhang WF; Xu ZS; Liu YP; Li Y; Zhan MX; Lu LG
Oncol Rep; 2018 Oct; 40(4):2215-2223. PubMed ID: 30015962
[TBL] [Abstract][Full Text] [Related]
14. VDR is a potential prognostic biomarker and positively correlated with immune infiltration: a comprehensive pan-cancer analysis with experimental verification.
Xia X; Xu F; Dai D; Xiong A; Sun R; Ling Y; Qiu L; Wang R; Ding Y; Lin M; Li H; Xie Z
Biosci Rep; 2024 May; 44(5):. PubMed ID: 38639057
[TBL] [Abstract][Full Text] [Related]
15. CPEB3 functions as a tumor suppressor in colorectal cancer via JAK/STAT signaling.
Fang Y; Zhong Q; Wang Y; Gu C; Liu S; Li A; Yan Q
Aging (Albany NY); 2020 Nov; 12(21):21404-21422. PubMed ID: 33146632
[TBL] [Abstract][Full Text] [Related]
16. KIF20A Predicts Poor Survival of Patients and Promotes Colorectal Cancer Tumor Progression through the JAK/STAT3 Signaling Pathway.
Zhang Q; Di J; Ji Z; Mi A; Li Q; Du X; Wang A; Wang A; Qin C
Dis Markers; 2020; 2020():2032679. PubMed ID: 32695240
[TBL] [Abstract][Full Text] [Related]
17. BNIPL‑2 expression is correlated with the prognosis and regulates the proliferation of colorectal cancer through CD44.
Gao L; Liu H; Yin N; Zuo S; Jin G; Hu Y; Hu D; Li Y; Song Q; Fei X
Mol Med Rep; 2019 Nov; 20(5):4073-4080. PubMed ID: 31485655
[TBL] [Abstract][Full Text] [Related]
18. CSRP2 suppresses colorectal cancer progression
Chen L; Long X; Duan S; Liu X; Chen J; Lan J; Liu X; Huang W; Geng J; Zhou J
Theranostics; 2020; 10(24):11063-11079. PubMed ID: 33042270
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
Front Immunol; 2022; 13():994828. PubMed ID: 36405728
[TBL] [Abstract][Full Text] [Related]
20. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
